Oxford BioMedica, Modex in diabetes deal

06 July 1999 17:36  [Source: ICIS news]

LONDON (CNI)--Oxford BioMedica said Tuesday it has teamed up with Swiss company Modex Therapeutics to develop cell-based therapies that can be implanted into the body, the first of which will be a treatment for insulin dependent diabetes.

Modex will use the UK company's LentiVector gene delivery technology to develop the therapies in combination with its own proprietary encapsulated cell systems.

The therapeutic implants for diabetes will contain glucose responsive, insulin-producing beta cell lines, and could replace daily injections, Oxford BioMedica said. It estimates the global market for diabetes medications at over $2bn (Euro1.96bn) and expects it to grow at an annual rate of about 9%.

Modex is a private venture-funded biotechnology company which specialises in encapsulated cell-based therapies that can be implanted into the body to treat chronic disorders.

By: Anna Williams
+44 208 652 3214

For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.

Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.

Printer Friendly